Heska Corp HSKA
We take great care to ensure that the data presented and summarized in this overview for HESKA CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HSKA
View allLatest Institutional Activity in HSKA
Top Purchases
Top Sells
About HSKA
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.
Insider Transactions at HSKA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 13
2023
|
Anthony C. Providenti Jr. EVP, Corporate Development |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,627
-100.0%
|
$8,115,240
$120.0 P/Share
|
Jun 13
2023
|
Anthony C. Providenti Jr. EVP, Corporate Development |
BUY
Grant, award, or other acquisition
|
Direct |
48,512
+23.41%
|
-
|
Jun 13
2023
|
Christopher D. Sveen CAO & General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,591
-100.0%
|
$3,310,920
$120.0 P/Share
|
Jun 13
2023
|
Christopher D. Sveen CAO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
19,105
+25.79%
|
-
|
Jun 13
2023
|
Catherine Grassman EVP, CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,684
-100.0%
|
$6,802,080
$120.0 P/Share
|
Jun 13
2023
|
Catherine Grassman EVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
42,423
+24.6%
|
-
|
Jun 13
2023
|
Eleanor F. Baker EVP, Managing Dir. & COO, scil |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,282
-100.0%
|
$3,513,840
$120.0 P/Share
|
Jun 13
2023
|
Eleanor F. Baker EVP, Managing Dir. & COO, scil |
BUY
Grant, award, or other acquisition
|
Direct |
20,813
+26.04%
|
-
|
Jun 13
2023
|
Kevin S. Wilson CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
310,506
-100.0%
|
$37,260,720
$120.0 P/Share
|
Jun 13
2023
|
Kevin S. Wilson CEO and President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
383,447
-100.0%
|
$46,013,640
$120.0 P/Share
|
Jun 13
2023
|
Kevin S. Wilson CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
211,375
+35.54%
|
-
|
Jun 13
2023
|
Scott Humphrey |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,881
-100.0%
|
$825,720
$120.0 P/Share
|
Jun 13
2023
|
Mark F Furlong |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,726
-100.0%
|
$567,120
$120.0 P/Share
|
Jun 13
2023
|
David E. Sveen |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
21,428
-100.0%
|
$2,571,360
$120.0 P/Share
|
Jun 13
2023
|
David E. Sveen |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,653
-100.0%
|
$2,598,360
$120.0 P/Share
|
Jun 13
2023
|
Robert L Antin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,189
-100.0%
|
$262,680
$120.0 P/Share
|
Jun 13
2023
|
Sharon J. Larson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,608
-100.0%
|
$1,032,960
$120.0 P/Share
|
Jun 13
2023
|
Steven M. Eyl EVP, CCO & Pres.scil |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,467
-100.0%
|
$7,736,040
$120.0 P/Share
|
Jun 13
2023
|
Steven M. Eyl EVP, CCO & Pres.scil |
BUY
Grant, award, or other acquisition
|
Direct |
37,167
+20.66%
|
-
|
Jun 13
2023
|
Joachim A. Hasenmaier |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,004
-100.0%
|
$240,480
$120.0 P/Share
|